Trial Profile
High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic Cell Support for Patients With Relapsed/Refractory Hodgkin's Disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Busulfan (Primary) ; Gemcitabine (Primary) ; Melphalan (Primary) ; Palifermin; Rituximab
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 01 Apr 2019 Status changed from active, no longer recruiting to completed.
- 14 Feb 2018 Planned End Date changed from 1 Jun 2018 to 1 Jun 2020.
- 14 Feb 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.